GHGroeninge
Kortrijk, Belgium
NCT Number: NCT03855969
Background:
Central venous catheters are frequently used during cancer treatment with the aim of venepreservation. It can facilitate venous access for the safe administration of irritating or vesicant intravenous cancer medications and / or other fluids, to collect blood samples or to ensure accurate venous access for contrast during medical imaging. In addition, this means more comfort for the patient who needs to be punctured less peripherally. However, central venous catheters can also be a source of bloodstream infections and other complications, leading to increased morbidity and hospital costs (1). In our hospital, there is a general practice that if an infection of the device is suspected, the central venous catheter should be removed if antibiotics do not seem or prove to be effective.
The objective of this trial is to assess the frequency of implanted port catheter-removal in cancer patients due to suspected infection of the device in a particular oncology center over a time period of seven years. Furthermore, evidence for real device infections (per/post-surgery) and the potential contribution of different (institution-specific) risk factors on device infection will be explored. There will be focused on implanted port catheters only, as this is the main used central venous access device within the oncological population.
Trial objectives:
The primary aim of this retrospective descriptive trial is to evaluate the frequency of implanted port catheter-removal in cancer patients due to suspected infection of the device, over a time period of seven years.
The secondary aim is to examine whether the device infection could be confirmed during or after removal of the device.
At last, the tertiary aim is to verify whether certain variables can be denoted as potential risk factors for central venous access infection. Selection of those variables of interest will be based on a thorough review of the literature and discussion with the responsible healthcare professionals.
Looking for future studies?
Notify MeAll sexes
Observational
Kortrijk, Belgium
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
-
We are interested in those patients for which a central venous access device was removed.
Time frame: 2012-2017
How many central venous access devices are removed due to a suspected infection of the device in cancer patients.
Time frame: 2012-2017
For how many of the central venous access devices that were removed due to suspected infection of the device could an infection be confirmed?
Time frame: 2012-2017
Is it possible to denote certain variables as potential risk factors for central venous access device infection?
General Hospital Groeninge
Other
Frequency of Central Venous Port Catheter Removal Due to Suspected Infection in Patients Diagnosed With Cancer at a Single Institution: A Retrospective Study.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04821466
End Stage Cancer, Hematologic Diseases
Truro, Cornwall, United Kingdom
View Trial DetailsNCT01345019
Blood Protein Disorders, Bone Diseases
Tucson, Arizona, United States
View Trial DetailsNCT04892160
Anemia, Anemia, Hemolytic
Milwaukee, Wisconsin, United States
View Trial DetailsNCT01300026
Cancer, Chronic Disease
Hackensack, New Jersey, United States
View Trial Details